This guide explains published facts and prices. It is not medical advice: a licensed provider who knows your health history decides what is right for you.
Is tirzepatide a GLP-1?
Yes, and more than that. The Zepbound label calls tirzepatide a GIP receptor and GLP-1 receptor agonist, so it is a GLP-1 medication that also acts on a second receptor, GIP (Zepbound prescribing information).
The label says nonclinical studies, meaning lab and animal research, suggest the added GIP may further contribute to the regulation of food intake (Zepbound prescribing information). For what GLP-1 itself does, see what is a GLP-1, and for how tirzepatide compares with semaglutide, see semaglutide or tirzepatide.
Is tirzepatide the same as Zepbound?
Zepbound is one brand of tirzepatide, and Mounjaro is another. The medication is the same, but each label lists its own approved uses:
- Zepbound: along with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or in adults with overweight and at least one weight-related health condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity (Zepbound prescribing information).
- Mounjaro: along with diet and exercise, to improve blood sugar control in adults and children 10 and older with type 2 diabetes (Mounjaro prescribing information).
If a price list says only "tirzepatide," ask which of these it is, or whether it is a compounded product.
How is tirzepatide taken?
The Zepbound label sets the same starting schedule for all of its uses (Zepbound prescribing information):
- Starting dose: 2.5 mg, injected under the skin once a week for 4 weeks. This dose is for starting treatment and is not approved as a maintenance dose.
- Stepping up: the dose goes up in 2.5 mg steps, each after at least 4 weeks, until the recommended maintenance dose is reached.
Mounjaro has its own label, so ask your provider about the schedule for the product you are prescribed.
What did the tirzepatide weight loss trial find?
In a trial published in 2022, 2,539 adults without diabetes, each with a body-mass index (BMI) of 30 or more, or 27 or more with at least one weight-related complication, were randomly assigned in four equal groups to once-weekly tirzepatide injections of 5 mg, 10 mg or 15 mg under the skin, or a placebo, for 72 weeks. The first 20 weeks were spent stepping up the dose (New England Journal of Medicine, 2022).
By week 72, people had lost an average of 15.0% of their body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, compared with 3.1% on placebo. The most common side effects with tirzepatide were digestive (gastrointestinal), most were mild to moderate, and they occurred mainly while the dose was being stepped up (New England Journal of Medicine, 2022).
Those are group averages from one trial, not a forecast for you. Ask your provider what they mean for your situation.
Is tirzepatide safe?
The Zepbound label answers with facts, not a yes or a no: who it is approved for, which is above, and these warnings, which a licensed provider weighs for one person (Zepbound prescribing information):
- Boxed warning: tirzepatide caused thyroid C-cell tumors in rats, more often at higher doses and with longer treatment, at exposure levels relevant to treatment in people. Whether Zepbound causes these tumors in humans, including medullary thyroid carcinoma (MTC), is unknown, since it has not been determined whether the rodent findings are relevant to humans.
- Who must not take it: people with MTC in their own or their family's medical history, and people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Other warnings: severe digestive side effects, acute kidney injury from loss of body fluids, acute gallbladder disease, acute pancreatitis, allergic reactions, low blood sugar, complications of diabetic retinopathy in people with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation.
- Pregnancy and birth control: the label says weight loss brings no benefit to a pregnant patient and may harm the fetus. If you take hormonal birth control pills, it advises switching to a method that is not a pill, or adding a barrier method, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase.
The most common side effects, reported in at least 5% of people taking Zepbound, are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss and acid reflux (Zepbound prescribing information).
What about compounded tirzepatide?
A monthly tirzepatide price at a med spa may not be for Zepbound or Mounjaro. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug (FDA's concerns with unapproved GLP-1 drugs). What else FDA says about compounded and unapproved versions is in what is a GLP-1.
So ask: is this Zepbound, Mounjaro or a compounded product, who prescribes it, and which pharmacy fills it?
What does tirzepatide cost at a Georgia med spa?
These are estimates from what Georgia med spas and skin clinics publish, not quotes, and we do not name any company.
- Tirzepatide, monthly program: estimated at $230 to $400+ per month. See what a month of tirzepatide covers.
- First consultation, where charged: estimated at $75 to $100+. See what consultations cost.
Because the dose is stepped up over time, ask whether the monthly price changes with it.
Questions to ask your provider
- Is this Zepbound, Mounjaro or a compounded product?
- Which dose will I start on, and when would it go up?
- I take birth control pills: what should I use while starting and stepping up?
- Which warnings on the label apply to me?
- Who do I call if I have side effects?
Ask for the product name and each month's price in writing before you begin.
Sources
- Zepbound (tirzepatide) injection, FDA-approved prescribing information (Eli Lilly, label effective August 2026), DailyMed, National Library of Medicine
- Mounjaro (tirzepatide) injection, FDA-approved prescribing information (Eli Lilly, label effective August 2026), DailyMed, National Library of Medicine
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration
Prices mentioned here come from our Georgia med spa cost ranges, built from the prices and cost guides Georgia med spas publish on their public websites, collected September and October 2026.